Interesting finding among the responders was that the plasma EBV of seven patients out of eight responders were detectable before treatment and already showed a decreasing trend during the first month of nivolumab treatment.
← all excerpts
Precision medicine in nasopharyngeal carcinoma: comprehensive review of past, present, and future prospect.
1
—
—